Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Vinciane Rebours

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0000-4525; OpenAlex author ID A5004987194. Sources: OpenAlex.

Their work

Papers
43 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
154
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 6 papers · 2020: 4 papers · 2021: 4 papers · 2022: 6 papers · 2023: 3 papers · 2024: 5 papers · 2025: 5 papers · 2026: 2 papers

Papers 43

  1. Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. Co-author DOI 10.1002/ijc.70581↗
  2. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  3. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  4. Causes, management, and prognosis of severe gastrointestinal bleedings in critically ill patients with pancreatic cancer: A retrospective multicenter study. Co-author DOI 10.1016/j.dld.2024.08.041↗
  5. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… Co-author DOI 10.1016/j.hpb.2025.04.009↗
  6. Laparoscopic pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared with open pancreatoduode… Co-author DOI 10.1016/j.surg.2024.09.041↗
  7. Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1177/17588359251403909↗
  8. Childhood and adulthood passive and active smoking, and the ABO group as risk factors for pancreatic cancer in women. Last author DOI 10.1002/ueg2.12487↗
  9. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  10. [Hereditary and familial forms of pancreatic adenocarcinoma: Genetic determinism, patients eligible for systematic screening, screening methods and results]. First author DOI 10.1016/j.bulcan.2023.11.002↗
  11. Clinical features and outcomes of patients with pancreatic cancer requiring unplanned medical ICU admission: A retrospective multicenter study. Co-author DOI 10.1016/j.dld.2023.08.049↗
  12. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  13. Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2023.102108↗
  14. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  15. Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Co-author DOI 10.1177/17588359231163776↗
  16. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
  17. Inflammatory potential of diet and pancreatic cancer risk in the EPIC study. Co-author DOI 10.1007/s00394-022-02809-y↗
  18. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  19. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk. Co-author DOI 10.1093/ije/dyab115↗
  20. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  21. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Co-author DOI 10.3389/fonc.2022.904327↗
  22. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. Co-author DOI 10.1002/ueg2.12123↗
  23. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.05.006↗
  24. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures. Co-author DOI 10.1158/1055-9965.epi-21-0169↗
  25. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  26. Consumption of nuts and seeds and pancreatic ductal adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition. Co-author DOI 10.1002/ijc.32415↗
  27. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. Co-author DOI 10.1007/s10654-019-00559-6↗
  28. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  29. Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. Co-author DOI 10.1177/2050640620939788↗
  30. Dietary folate intake and pancreatic cancer risk: Results from the European prospective investigation into cancer and nutrition. Co-author DOI 10.1002/ijc.31830↗
  31. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Co-author DOI 10.1002/ijc.31900↗
  32. Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. Co-author DOI 10.1111/cge.13629↗
  33. Socioeconomic Effect of Education on Pancreatic Cancer Risk in Western Europe: An Update on the EPIC Cohorts Study. Co-author DOI 10.1158/1055-9965.epi-18-1153↗
  34. Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition o… Co-author DOI 10.1177/2050640618824910↗
  35. Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer. First author DOI 10.3748/wjg.v25.i34.5082↗
  36. Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study. Co-author DOI 10.1002/ijc.31367↗
  37. Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort. Co-author DOI 10.1002/ijc.31797↗
  38. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.24084↗
  39. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Last author DOI 10.18632/oncotarget.25458↗
  40. Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition… Co-author DOI 10.1002/ijc.30590↗
  41. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Co-author DOI 10.1002/ijc.30790↗
  42. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Co-author DOI 10.1530/erc-16-0269↗
  43. Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318238379d↗

Closest collaborators

The 25 strongest of 154 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 16 shared papers, 2016–2026 · strength 2.27
  2. Louis de Mestier · 13 shared papers, 2016–2026 · strength 1.85
  3. Pascal R. Hammel · 16 shared papers, 2012–2026 · strength 1.80
  4. Jean‐Baptiste Bachet · 10 shared papers, 2021–2026 · strength 1.56
  5. Rémy Nicolle · 10 shared papers, 2021–2026 · strength 1.50
  6. Alain Sauvanet Sauvanet · 7 shared papers, 2012–2025 · strength 1.13
  7. Nelson Dusetti · 7 shared papers, 2022–2026 · strength 1.08
  8. Verena Andrea Katzke · 12 shared papers, 2017–2026 · strength 0.90
  9. Juan Iovanna · 6 shared papers, 2022–2025 · strength 0.89
  10. Safi Dokmak · 4 shared papers, 2019–2025 · strength 0.83
  11. Anne Couvelard Benveniste · 6 shared papers, 2012–2025 · strength 0.80
  12. Olivia Hentic Dhome · 4 shared papers, 2021–2025 · strength 0.80
  13. Magali Svrcek · 5 shared papers, 2021–2023 · strength 0.66
  14. Cindy Neuzillet · 5 shared papers, 2016–2025 · strength 0.64
  15. Anthony Turpin · 4 shared papers, 2021–2026 · strength 0.64
  16. Emmanuel Mitry · 4 shared papers, 2022–2026 · strength 0.63
  17. Rudolf Kaaks · 8 shared papers, 2017–2026 · strength 0.60
  18. Anne‐Laure Védié · 3 shared papers, 2018–2025 · strength 0.53
  19. Mickaël Lesurtel · 2 shared papers, 2025 · strength 0.51
  20. Thierry Conroy · 3 shared papers, 2024–2026 · strength 0.51
  21. James Biagi · 3 shared papers, 2024–2026 · strength 0.51
  22. Aurélien Lambert · 3 shared papers, 2024–2026 · strength 0.51
  23. Daniel John Renouf · 3 shared papers, 2024–2026 · strength 0.51
  24. Eric J. Duell · 9 shared papers, 2017–2020 · strength 0.50
  25. Maxime Ronot · 2 shared papers, 2025 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.